GleamWall
中文EN

WVE Wave Life Sciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1631574 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.6%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-320.9%
Net margin-296.9%
FCF margin-293.8%
EBITDA margin-316.1%

Returns

ROE-80.0%
ROA-56.2%
ROIC (approx.)-270.5%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets20.9%
Debt / equity0.00x
Current ratio8.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$13.16M$2.27M$38.25M$17.25M$7.61M$8.70M$9.18M—
R&D expense$53.84M$51.29M$47.44M$52.81M$45.87M$43.47M$40.62M$44.65M
SG&A expense$25.36M$24.78M$22.10M$20.90M$18.09M$17.99M$18.36M$16.14M
Operating income-$66.05M-$73.80M-$31.30M-$56.47M-$56.35M-$52.76M-$49.80M$22.97M
Pretax income-$61.91M-$69.36M-$26.09M-$53.18M-$53.85M-$50.47M-$46.88M$29.25M
Income tax$0$0$0$0$0$0$0$0
Net income-$61.91M-$69.36M-$26.09M-$53.18M-$53.85M-$50.47M-$46.88M$29.25M
EBITDA-$65.17M-$72.94M-$30.46M-$55.62M-$55.50M-$51.89M-$48.93M$23.87M
EPS (basic)-0.30-0.34-0.13—-0.32-0.31-0.29—
EPS (diluted)-0.30-0.34-0.13—-0.32-0.31-0.29—
Weighted avg. shares (diluted)204.22M204.01M200.17M—167.74M163.99M162.57M—
Balance sheet
Cash & equivalents$197.31M$368.01M$544.59M$602.07M$196.22M$208.48M$243.07M$302.08M
Short-term investments$233.43M——$0————
Receivables$12.00M$888,000$0$1.28M$10.00M$1.62M—$1.42M
Current assets$458.63M$507.51M$561.27M$614.81M$215.49M$223.56M$257.98M$320.39M
PP&E, net$6.24M$6.83M$7.08M$7.41M$8.20M$9.04M$9.57M$10.13M
Total assets$507.93M$558.32M$583.54M$638.50M$241.38M$252.35M$288.34M$352.21M
Current liabilities$54.76M$50.81M$49.83M$95.06M$85.90M$87.41M$87.37M$110.95M
Total liabilities$105.99M$104.80M$71.81M$112.27M$108.95M$105.22M$108.67M$134.82M
Shareholders' equity$401.94M$453.52M$511.73M$518.36M$124.55M$139.27M$171.80M$209.51M
Shares outstanding197.21M193.28M192.34M0160.29M155.67M154.09M153.04M
Cash flow statement
Operating cash flow-$60.14M-$53.58M-$59.55M-$33.78M-$44.67M-$46.01M-$63.04M-$43.65M
Capital expenditure$15,000$884,000$438,000-$1,000$248,000$306,000$165,000$86,000
Free cash flow-$60.16M-$54.47M-$59.99M-$33.77M-$44.91M-$46.32M-$63.20M-$43.73M
Investing cash flow-$110.86M-$123.45M-$438,000$1,000-$248,000-$306,000-$165,000-$86,000
Financing cash flow$433,000$330,000$2.53M$439.69M$32.69M$11.69M$4.16M$34.98M
Depreciation & amortization$880,000$858,000$841,000$844,000$856,000$865,000$875,000$907,000
Stock-based compensation$10.29M$10.73M$9.06M$7.35M$6.47M$6.20M$4.95M$3.24M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.